Article Information
History
- February 4, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Joanne D Stockton, PhD1,
- Louise Tee, MSc1,
- Celina Whalley, MSc1,
- Jonathan James, PhD1,
- Mark Dilworth, FRCS1,2,
- Rachel Wheat, MSc1,
- Thomas Nieto, MRCS1,2,
- Ian Geh, FRCR2 and
- Andrew D Beggs, FRCS PhD1,2,*
- 1Institute of Cancer & Genomic Science, University of Birmingham
- 2University Hospitals Birmingham NHS Foundation Trust
- ↵*Correspondence to: Andrew Beggs, Surgical Research Laboratory, Institute of Cancer & Genomic Science, University of Birmingham, Vincent Drive, Birmingham, B15 2TT; email: a.beggs{at}bham.ac.uk
Contributorship: Manuscript: ADB, JS, IG, DM; Molecular analysis: JS, LT, CW, JJ, MD, TN, AB; Sample acquisition and patient cohort: IG, DM, ADB.
Posted February 04, 2020.
Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden
